Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOnKure Therapeutics, Inc.

OnKure Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.865 USD 0.34 ( 13.47%)
Last update at 2026-11-06T21:00:00Z
VOLUME
555764
Market Cap
118.65M

Momentum Score

…

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.31
Low
2.87
High
52 Week Price Range
2.23
Low
5.38
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.52
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-46.91%
Net Debt
-58.50M
ROCE
-105.91%
Diluted EPS TTM
-2.97

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.52M -52.67M -35.31M -29.51M -39.77M
Net income -59.52M -52.67M -35.31M -29.51M -39.77M
Selling general administrative 14.69M 10.59M 4.82M 3.90M -
Gross profit -0.83M -0.66M -0.56M -0.53M -0.05M
Reconciled depreciation 0.83M 0.66M 0.56M 0.39M -
Ebit -59.52M -52.37M -35.31M -29.51M -39.77M
Ebitda -58.69M -51.71M -34.75M -29.12M -39.72M
Depreciation and amortization 0.83M 0.66M 0.56M 0.39M 0.05M
Operating income -62.95M -54.39M -36.93M -29.77M -39.82M
Other operating expenses 62.95M 54.39M 36.93M 29.77M 39.82M
Interest expense 0.01M 0.30M 0.00M - -
Interest income 3.44M 2.01M 1.62M 0.25M -
Net interest income 3.43M 1.71M 1.62M 0.25M -
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 62.12M 54.39M 36.93M 29.77M 39.77M
Cost of revenue 0.83M 0.66M 0.56M 0.53M 0.05M
Total other income expense net 3.43M 1.71M 1.62M 0.25M 0.05M
Net income from continuing ops -59.52M -52.67M -35.31M -29.51M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 62.12M 114.91M 35.73M 16.00M 154.02M
Other current assets 1.79M 2.24M 3.89M 2.08M 6.06M
Total liab 5.93M 11.08M 137.58M 70.42M 6.81M
Total stockholder equity 56.18M 103.83M -101.84M -54.42M 147.21M
Other current liab 3.94M 7.03M 3.66M 2.87M 6.20M
Common stock 0.00M 0.00M - 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M -
Retained earnings -214.24M -154.72M -102.05M -57.07M -84.73M
Other assets - - - - 0.00M
Cash 59.05M 110.76M 29.88M 11.54M 124.66M
Total current liabilities 5.92M 10.53M 7.29M 5.54M 6.20M
Net debt -58.50M -109.68M -29.20M -10.91M -124.66M
Short term debt 0.55M 0.54M 0.21M 0.15M -
Short long term debt total 0.55M 1.08M 0.67M 0.64M -
Other stockholder equity 270.42M 258.55M 0.21M 2.65M 231.90M
Total current assets 60.84M 113.00M 33.77M 13.62M 153.73M
Short term investments - - - 81.25M 23.01M
Accounts payable 1.43M 2.97M 3.42M 2.52M -
Accumulated other comprehensive income - - - -0.04M 0.03M
Non currrent assets other 0.27M 0.11M 0.06M 0.33M 0.08M
Non current assets total 1.28M 1.90M 1.97M 2.38M 0.29M
Capital lease obligations 0.55M 1.08M 0.67M 0.64M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 15.87M -0.25M -1.13M -
Total cashflows from investing activities -0.05M 15.87M -0.25M -1.13M -23.38M
Net borrowings 0.00M 6.00M 0.00M - -
Total cash from financing activities 0.16M 116.13M 53.12M 26.46M 132.41M
Net income -59.52M -52.67M -35.31M -29.51M -39.77M
Change in cash -51.71M 80.89M 18.33M -1.62M 71.05M
Begin period cash flow 110.76M 29.88M 11.54M 13.16M 53.61M
End period cash flow 59.05M 110.76M 29.88M 11.54M 124.66M
Total cash from operating activities -51.83M -51.12M -34.55M -26.95M -37.98M
Issuance of capital stock 0.00M 58.91M 53.85M 27.84M -
Depreciation 0.83M 0.66M 0.56M 0.39M 0.05M
Other cashflows from investing activities - - - -44.10M -
Other cashflows from financing activities -0.04M 51.22M 53.06M 26.12M -
Capital expenditures 0.05M 0.05M 0.25M 1.13M 0.20M
Change in working capital -4.78M -3.95M 0.01M 2.12M -2.80M
Stock based compensation 11.63M 4.53M 0.20M 0.05M -
Other non cash items 0.01M 0.32M - - 4.54M
Free cash flow -51.87M -51.17M -34.79M -28.09M -38.18M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
OKUR
OnKure Therapeutics, Inc.		 0.34
13.47%		 2.87 - - - 0.70 0.03
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

6707 Winchester Circle, Boulder, CO, United States, 80301

720-307-2892

https://onkuretherapeutics.com

45

Name Title Year Born
Dr. Nicholas A. Saccomano Ph.D. President, CEO & Director 1959
Mr. Jason A. Leverone CPA Chief Financial Officer 1974
Dr. Isaac Manke Ph.D. Senior VP of Business Development & Director 1977
Dr. Samuel Agresta M.D., M.P.H. Chief Medical Officer 1973
Dr. Dylan Hartley Ph.D. Chief Scientific Officer 1969
Mr. Rogan P. Nunn J.D. General Counsel & Secretary NA
Dr. James Blake Ph.D. Senior Vice President of Computational Drug Discovery NA
Dr. Kevin S. Litwiler Ph.D. Senior Vice President of DMPK & Clinical Pharmacology NA
Dr. Mark L. Boys Ph.D. Senior Vice President of Discovery Chemistry NA
Ms. Roberta Alton Senior Vice President of Clinical Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…